GlassScriptPhysician profile
Cary Cummings
NPI 1366407165
$2,998.05
in general payments reported to CMS, 2019-2025
26 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $25.11 · 2021: $48.16 · 2022: $839 · 2023: $1,021 · 2024: $147 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,298.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $499.90 | 2019 | |
| Abbvie INC. | $399.00 | 2019-2023 | Qulipta, Ubrelvy, Vraylar |
| Bayer Healthcare Pharmaceuticals INC. | $311.40 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $220.89 | 2019-2025 | Xifaxan |
| Amgen INC. | $207.37 | 2019-2023 | Repatha, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $195.49 | 2023-2025 | Cabtreo, Arazlo, Jublia |
| Lilly USA, LLC | $183.19 | 2019-2023 | Mounjaro |
| Glaxosmithkline, LLC. | $159.92 | 2019-2023 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $143.90 | 2019-2023 | Farxiga |
| Novo Nordisk INC | $112.29 | 2019-2023 | Ozempic, Rybelsus |
| Travere Therapeutics, INC. | $104.14 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $72.44 | 2019 | |
| Nestle Healthcare Nutrition INC. | $69.00 | 2022-2023 | |
| Pfizer INC. | $55.82 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $42.10 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $31.58 | 2023 | Terlivaz |
| Kowa Pharmaceuticals America, INC. | $29.58 | 2022-2023 | Livalo, Seglentis |
| Philips North America LLC | $28.59 | 2022-2023 | |
| Ani Pharmaceuticals, INC. | $26.08 | 2023 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.32 | 2023 | Jardiance |
| Exact Sciences Corporation | $17.89 | 2023 | Cologuard Collection Kit |
| Neurelis, INC. | $17.26 | 2023 | Valtoco |
| Vifor Pharma, INC. | $15.99 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.32 | 2023 | Ultomiris |
| Greenwich Biosciences, INC. | $11.82 | 2019 | |
| Daiichi Sankyo INC. | $10.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cary Cummings listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.